Mannkind Afrezza FDA Panel Live Blog

Welcome to the Mannkind ( MNKD) Afrezza FDA Panel live blog.

The FDA has gathered a group of medical experts together today to review and discuss Afrezza, an inhaled, rapid-acting insulin designed for the treatment of Type 1 and Type 2 diabetes. At the end of today's all-day meeting, the experts will vote on whether or not to recommend Afrezza's approval. 

This is Mannkind's third attempt at getting Afrezza approved. The FDA rejected the product both times previously. For this resubmission, Mannkind conducted two phase III studies of Afrezza, one each in Type 1 and Type 2 diabetes. 

TheStreet's biotech columnist Adam Feuerstein published a preview of today's panel on Monday

Follow along all the action today as Feuerstein live blogs the Afrezza panel.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind